The safety of finasteride for female-to-male (FTM) transgender patients

Phase 2

• Conditions: Female-to-male (FTM) transgender; Gender identity disorder, gender dysphoria

• Registration Number: JPRN-jRCTs061210040
• Lead Sponsor: Tominaga Yusuke

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-10-07
• Last Update Posted: 1 April 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 5

Inclusion Criteria

(1) Patients diagnosed with female-to-male (FTM) transgender who are 20 years of age or older and younger than 60 years at the time of obtaining consent
(2) Receiving testosterone replacement therapy in our department.
(3) Have androgenetic alopecia (II or higher in the Modified Norwood-Hamilton Classification)
(4) Provide sufficient informed consent to participate in the study, and get his or her voluntary written consent.

Exclusion Criteria

(1) History of allergy, which is associated with finasteride.
(2) Liver dysfunction.
(3) Post-sex reassignment surgery.
(4) Severe mental disorders (e.g., severe depression).
(5) Inappropriate for enrollement decided by the attending physician.

Study & Design

• Study Type: Interventional
• Study Design: Not specified